docetaxel anhydrous has been researched along with vtx-2337 in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (vtx-2337) | Trials (vtx-2337) | Recent Studies (post-2010) (vtx-2337) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 14 | 4 | 14 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, CS; Li, F; Lv, H; Wan, Y; Zhang, R | 1 |
1 other study(ies) available for docetaxel anhydrous and vtx-2337
| Article | Year |
|---|---|
DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; Benzazepines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Immunologic Factors; Immunotherapy; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Small Molecule Libraries; Transplantation, Homologous; Tumor Microenvironment | 2021 |